BTR,
If I were MRK, I get the checkbook out now. If Rida succeeds in sarcoma and IF it starts to show efficacy in solid tumors, then Berger's price will be off the charts. PGS knows something about mTor, so maybe he can comment. I think he mentioned somewhere that he has seen mTor efficacy in cardiology.
I agree with with "Aria" that MRK is the most logical partner. Pona gives them a competitive drug for BMY and NVS. And the ALK inhibitor gives them a competitive drug against PFE.
But who said these things were logical?
Bladerunner
News 
Market Data 
Discover 
